A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Miren Taberna
Miren Taberna
Marc Oliva
Ricard Mesía

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Prolonged Survival of the Patient with Head and Neck Cancer with Squamous Cell Carcinoma treated with Cetuximab: A Case Report

Das, Pratap Kishore
Patowary, Jayanta

January 2020

Introduction: Cetuximab, an epidermal growth factor (EGFR) inhibitor has radio sensitizing activity ...

Image_3_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

Seiwert, Tanguy Y.
Kochanny, Sara
Wood, Kevin
Worden, Francis P.
Adkins, Douglas
Wade, James L.
Sleckman, Bethany G.
Anderson, Daniel
Brisson, Ryan J.
Karrison, Theodore
Stadler, Walter M.
Vokes, Everett E.

July 2020

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/155947/1/cncr32929_am.pdfhttps://deepb...

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

Gilbert, Jill
Schell, Michael J.
Zhao, Xiuhua
Murphy, Barbara
Tanvetyanon, Tawee
Leon, Marino E.
Hayes, D. Neil
Haigentz, Missak
Saba, Nabil
Nieva, Jorge
Bishop, Justin
Sidransky, David
Ravi, Rajani
Bedi, Atul
Chung, Christine H.

January 2015

A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and...

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Haddad, Robert
Concha‐benavente, Fernando
Blumenschein, George
Fayette, Jerome
Guigay, Joel
Colevas, A. Dimitrios
Licitra, Lisa
Kasper, Stefan
Vokes, Everett E.
Worden, Francis
Saba, Nabil F.
Tahara, Makoto
Jayaprakash, Vijayvel
Lynch, Mark
Li, Li
Gillison, Maura L.
Harrington, Kevin J.
Ferris, Robert L.

September 2019

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151309/1/cncr32190_am.pdfhttps://deepb...

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Santin, Alessandro D.
Sill, Michael W.
McMeekin, D. Scott
Leitao, Mario M.
Brown, Jubilee
Sutton, Gregory P.
Van Le, Linda
Griffin, Patricia
Boardman, Cecelia H.

January 2011

The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerabil...

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Mohamedtaki A Tejani
Roger B Cohen
Ranee Mehra

June 2010

Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...

Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin

Corry, June
Bressel, Mathias
Fua, Tsien
Herschtal, Alan
Solomon, Benjamin
Porceddu, Sandro V.
Wratten, Chris
Rischin, Danny

July 2017

Purpose: To report on the outcomes of a novel treatment regimen for patients with locally advanced h...

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

P. Bossi
R. Miceli
L..D. Locati
D. Ferrari
S. Vecchio
G. Moretti
N. Denaro
F. Caponigro
M. Airoldi
C. Moro
E. Vaccher
A. Sponghini
A. Caldara
S.G. Rinaldi
F. Ferrau
F. Nol&#232
S. Lo Vullo
F. Tettamanzi
L. Hollander
L.F.L. Licitra

November 2017

B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the eff...

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bourhis, Jean
Rivera, Fernando
Mesia, Ricard
Awada, Ahmad
Geoffrois, Lionel
Borel, Christian
Humblet, Yves
Lopez-Pousa, Antonio
Hitt, Ricardo
Vega Villegas, M Eugenia
Duck, Lionel
Rosine, Dominique
Amellal, Nadia
Schueler, Armin
Harstrick, Andreas

January 2006

PURPOSE: This was an open, randomized, multicenter, phase I/II study to investigate the safety and t...

Table_2_Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.DOCX

Miren Taberna (5108825)
Marc Oliva (2187229)
Ricard Mesía (5108840)

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Image_2_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

Table_1_Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.DOCX

Miren Taberna (5108825)
Marc Oliva (2187229)
Ricard Mesía (5108840)

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Image_1_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Miren Taberna
Miren Taberna
Marc Oliva
Ricard Mesía

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Prolonged Survival of the Patient with Head and Neck Cancer with Squamous Cell Carcinoma treated with Cetuximab: A Case Report

Das, Pratap Kishore
Patowary, Jayanta

January 2020

Introduction: Cetuximab, an epidermal growth factor (EGFR) inhibitor has radio sensitizing activity ...

Image_3_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

Seiwert, Tanguy Y.
Kochanny, Sara
Wood, Kevin
Worden, Francis P.
Adkins, Douglas
Wade, James L.
Sleckman, Bethany G.
Anderson, Daniel
Brisson, Ryan J.
Karrison, Theodore
Stadler, Walter M.
Vokes, Everett E.

July 2020

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/155947/1/cncr32929_am.pdfhttps://deepb...

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

Gilbert, Jill
Schell, Michael J.
Zhao, Xiuhua
Murphy, Barbara
Tanvetyanon, Tawee
Leon, Marino E.
Hayes, D. Neil
Haigentz, Missak
Saba, Nabil
Nieva, Jorge
Bishop, Justin
Sidransky, David
Ravi, Rajani
Bedi, Atul
Chung, Christine H.

January 2015

A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and...

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Haddad, Robert
Concha‐benavente, Fernando
Blumenschein, George
Fayette, Jerome
Guigay, Joel
Colevas, A. Dimitrios
Licitra, Lisa
Kasper, Stefan
Vokes, Everett E.
Worden, Francis
Saba, Nabil F.
Tahara, Makoto
Jayaprakash, Vijayvel
Lynch, Mark
Li, Li
Gillison, Maura L.
Harrington, Kevin J.
Ferris, Robert L.

September 2019

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151309/1/cncr32190_am.pdfhttps://deepb...

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Santin, Alessandro D.
Sill, Michael W.
McMeekin, D. Scott
Leitao, Mario M.
Brown, Jubilee
Sutton, Gregory P.
Van Le, Linda
Griffin, Patricia
Boardman, Cecelia H.

January 2011

The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerabil...

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Mohamedtaki A Tejani
Roger B Cohen
Ranee Mehra

June 2010

Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...

Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin

Corry, June
Bressel, Mathias
Fua, Tsien
Herschtal, Alan
Solomon, Benjamin
Porceddu, Sandro V.
Wratten, Chris
Rischin, Danny

July 2017

Purpose: To report on the outcomes of a novel treatment regimen for patients with locally advanced h...

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

P. Bossi
R. Miceli
L..D. Locati
D. Ferrari
S. Vecchio
G. Moretti
N. Denaro
F. Caponigro
M. Airoldi
C. Moro
E. Vaccher
A. Sponghini
A. Caldara
S.G. Rinaldi
F. Ferrau
F. Nol&#232
S. Lo Vullo
F. Tettamanzi
L. Hollander
L.F.L. Licitra

November 2017

B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the eff...

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bourhis, Jean
Rivera, Fernando
Mesia, Ricard
Awada, Ahmad
Geoffrois, Lionel
Borel, Christian
Humblet, Yves
Lopez-Pousa, Antonio
Hitt, Ricardo
Vega Villegas, M Eugenia
Duck, Lionel
Rosine, Dominique
Amellal, Nadia
Schueler, Armin
Harstrick, Andreas

January 2006

PURPOSE: This was an open, randomized, multicenter, phase I/II study to investigate the safety and t...

Table_2_Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.DOCX

Miren Taberna (5108825)
Marc Oliva (2187229)
Ricard Mesía (5108840)

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Image_2_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

Table_1_Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.DOCX

Miren Taberna (5108825)
Marc Oliva (2187229)
Ricard Mesía (5108840)

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Image_1_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Miren Taberna
Miren Taberna
Marc Oliva
Ricard Mesía

May 2019

Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...

Prolonged Survival of the Patient with Head and Neck Cancer with Squamous Cell Carcinoma treated with Cetuximab: A Case Report

Das, Pratap Kishore
Patowary, Jayanta

January 2020

Introduction: Cetuximab, an epidermal growth factor (EGFR) inhibitor has radio sensitizing activity ...

Image_3_Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.TIFF

Tomohiro Enokida (5686601)
Susumu Okano (5686604)
Takao Fujisawa (413999)
Yuri Ueda (5686607)
Shinya Uozumi (5686610)
Makoto Tahara (5686613)

August 2018

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and pa...

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Abstract

Extracted data

Related items

Related items